ACELYRIN, INC. Announces Positive Phase 1/2 Proof-of-Concept Data for Lonigutamab, First Subcutaneous Anti-IGF-1R to Demonstrate Clinical Responses in Thyroid …

Rapid improvements demonstrated for proptosis, clinical activity scores, and diplopia versus placebo with a favorable safety profile Phase 2b/3 trial to be initiated in the second half of 2024 Conference call to review these data to be held at 8:30 a.m. ET today LOS ANGELES, March 20, 2024 (GLOBE…#phase2b3 #phase12 #cas #iv #shaoleelin #phd #acelyrin #cohort1 #cohort2 #teprotumumabsmith

Source: Reuters: Health - March 20, 2024 Category: Consumer Health News Source Type: news